ExodusPoint Capital Management’s Y-mAbs Therapeutics YMAB Stock Holding History

ExodusPoint Capital Management’s Portfolio YMAB Stock Details YMAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-32,256	Closed	-$253K	–	2078
2024 Q4	$253K	Buy	+32,256	New	+$393K	﹤0.01%	1322
2024 Q1	–	Sell	-26,224	Closed	-$179K	–	2029
2023 Q4	$179K	Buy	26,224 +12,098	+86%	+$70K	﹤0.01%	1300
2023 Q3	$77K	Sell	14,126 -12,374	-47%	-$72.1K	﹤0.01%	1602
2023 Q2	$180K	Buy	+26,500	New	+$199K	﹤0.01%	1695
2021 Q4	–	Sell	-17,399	Closed	-$497K	–	2669
2021 Q3	$497K	Buy	17,399 +399	+2%	+$12.6K	0.01%	1386
2021 Q2	$575K	Buy	+17,000	New	+$546K	0.01%	1291
2020 Q3	–	Sell	-5,094	Closed	-$220K	–	2292
2020 Q2	$220K	Buy	+5,094	New	+$193K	0.01%	1470

Other funds holding YMAB

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

ExodusPoint Capital Management's YMAB Position: Q1 2025 in Review

ExodusPoint Capital Management sold out of Y-mAbs Therapeutics (YMAB) in Q1 2025, closing a stake of 32,256 shares — an estimated $253K sold.

ExodusPoint Capital Management first reported a position in YMAB in Q2 2020 and held it in 7 quarters. The position peaked at $575K in Q2 2021. 102 funds tracked by Wall St. Rank hold YMAB as of Q1 2025.

ExodusPoint Capital Management reported no remaining Y-mAbs Therapeutics position as of Q1 2025 after selling out during the quarter.
ExodusPoint Capital Management sold 32,256 Y-mAbs Therapeutics shares in Q1 2025, an estimated $253K.
ExodusPoint Capital Management first reported a position in Y-mAbs Therapeutics in Q2 2020 and held it in 7 quarters.
ExodusPoint Capital Management's Y-mAbs Therapeutics position peaked at $575K in Q2 2021.
102 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q1 2025.

Based on ExodusPoint Capital Management's 13F filing for Q1 2025, filed 14 May 2025.